2023 World Conference on Lung Cancer (Posters)-P1.28. Should Older Patients with Stage Iii Non-small-Cell Lung Cancer Be Treated with Concurrent Chemoradiotherapy?

P1.28. Should Older Patients with Stage Iii Non-small-Cell Lung Cancer Be Treated with Concurrent Chemoradiotherapy? - PDF(Abstract)

Back to course

Pdf Summary

This study evaluated the outcomes of older patients with stage III non-small-cell lung cancer (NSCLC) who were treated with concurrent chemoradiotherapy (CRT). The study aimed to determine whether older age alone should be a reason to deny CRT treatment to otherwise fit patients. The data was collected from the Australian Registry and Biobank of Thoracic Cancers (AURORA).<br /><br />A total of 265 patients with stage III NSCLC were treated with CRT between January 2012 and June 2022. The median follow-up was 5.4 years. Of these patients, 63% were 70 years or older, while 37% were younger than 70. The median overall survival (OS) was found to be 2.21 years.<br /><br />The study found that older age was not associated with worse OS in patients treated with CRT. In univariable analysis, the hazard ratio (HR) per 10 years increase in age at diagnosis was 1.07. However, after adjusting for age, sex, baseline weight loss, ECOG performance status, smoking status, and completion of the full course of CRT, the HR was 1.02, indicating that age was not a significant factor in predicting survival.<br /><br />On the other hand, the study did find that poorer ECOG performance status, weight loss, and tobacco use were associated with worse OS. These factors were found to have a significant impact on survival outcomes.<br /><br />Based on the findings, the study concludes that older age should not be a reason to deny CRT treatment to fit patients with stage III NSCLC. The study suggests that CRT may reasonably be given to older patients who are otherwise fit.<br /><br />In summary, this study explores the outcomes of older patients with stage III NSCLC treated with concurrent CRT. The data suggests that age alone should not be a determining factor in the decision to administer CRT, and older patients may benefit from this treatment if they are otherwise fit.

Asset Subtitle

Neil Wallace

Meta Tag

Speaker Neil Wallace

Topic Local-Regional NSCLC

Keywords

older patients

stage III non-small-cell lung cancer

NSCLC

concurrent chemoradiotherapy

CRT

Australian Registry and Biobank of Thoracic Cancers

AURORA

overall survival

ECOG performance status

tobacco use